Antigenics receives Nasdaq delisting warning
This article was originally published in Scrip
Executive Summary
Antigenicshas received a Nasdaq warning letter informing the company that it does not have the required $50 million minimum market value of listed securities set out in the index's Marketplace Rule. The company has also failed to meet the alternative rule that requires $50 million of total assets and $50 million of total revenue for either the most recently completed fiscal year or two of the past three fiscal years. Antigenics has until December 22nd to regain compliance with the rules and must have listed securities with a market value of $50 million or more for 10 consecutive days. Antigenics did not state how it plans to regain compliance but said that if it was delisted, it might appeal against the Nasdaq's decision or apply to transfer its securities from the Nasdaq Global Market to the Capital Market.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.